{"id":337,"date":"2023-09-11T20:02:50","date_gmt":"2023-09-11T20:02:50","guid":{"rendered":"http:\/\/www.precicolon.es\/?page_id=337"},"modified":"2023-10-14T17:08:36","modified_gmt":"2023-10-14T17:08:36","slug":"publications-fibhnjs","status":"publish","type":"page","link":"https:\/\/www.precicolon.es\/?page_id=337","title":{"rendered":"Publications AP"},"content":{"rendered":"\n

During these years the AP group<\/strong> has established collaborations with different national and international groups, in the field of coordinated projects and projects of excellence of the ISCIII, European projects, of the Community of Madrid, etc. Within the IIS-FJD, we actively collaborate with numerous groups, both within the Cancer Area and other programs. In addition, our group is part of the CIBERONC of the ISCIII, within the Breast Cancer program. As a consequence of this extensive collaboration, our group has published relevant articles describing numerous aspects of the molecular mechanisms of tumor resistance: chemoresistance studies (Crist\u00f3bal, 2020), resistance to targeted therapies (Zazo, 2020; Gonz\u00e1lez-Alonso, 2020; Sabbaghi, 2017), resistance to hormone therapy (Crist\u00f3bal, 2016), of tumor cell reprogramming (Gawrzak, 2018), translational studies in clinical trials (Lluch, 2019), the role of miRNA (Tormo, 2019), as well as the role of the immune response (Peg, 2020; Muntasell, 2019; Muntasell, 2018). Last but not least, our laboratory has cultivated since its inception the training aspect, providing the opportunity to perform doctoral theses, TFM, TFG and training stays to numerous students, residents and researchers.<\/p>\n\n\n\n

    \n
  1. Scientific Article 2022.<\/strong> Santos A, Crist\u00f3bal I, Rubio J, Caram\u00e9s C, Luque M, Sanz-Alvarez M, Morales-Gallego M, Madoz-G\u00farpide J, Rojo F<\/strong>, Garc\u00eda-Foncillas J. MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer Patients. Int J Mol Sci. 2022 Feb 17;23(4):2203. doi: 10.3390\/ijms23042203. PMID: 35216319; PMCID: PMC8875596.<\/li>\n\n\n\n
  2. Scientific Article 2022.<\/strong> Luque M, Crist\u00f3bal I, Sanz-\u00c1lvarez M, Santos A, Zazo S, Eroles P, Arp\u00ed O, Rovira A, Albanell J, Madoz-G\u00farpide J, Garc\u00eda-Foncillas J, Rojo F<\/strong>. CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer. J Clin Med. 2022 Mar 14;11(6):1610. doi: 10.3390\/jcm11061610. PMID: 35329936; PMCID: PMC8955826.<\/li>\n\n\n\n
  3. Scientific Article 2021.<\/strong> Luque M, Sanz-\u00c1lvarez M, Santamar\u00eda A, Zazo S, Crist\u00f3bal I, de la Fuente L, M\u00ednguez P, Eroles P, Rovira A, Albanell J, Madoz-G\u00farpide J, Rojo F.<\/strong> Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer. Int J Mol Sci. 2021 Dec 10;22(24):13297. doi: 10.3390\/ijms222413297. PMID: 34948097; PMCID: PMC8706990.<\/li>\n\n\n\n
  4. Scientific Article 2021.<\/strong> Crist\u00f3bal I, Santos A, Rubio J, Caram\u00e9s C, Zazo S, Sanz-\u00c1lvarez M, Luque M, Madoz-G\u00farpide J, Rojo F<\/strong>, Garc\u00eda-Foncillas J. Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients. Cancers (Basel). 2021 Oct 5;13(19):5003. doi: 10.3390\/cancers13195003. PMID: 34638487; PMCID: PMC8507802.<\/li>\n\n\n\n
  5. Scientific Article 2021.<\/strong> Guardia C, Bianchini G, Arp\u00ed-LLuci\u00e0 O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jim\u00e9nez L, Sabbaghi M, Pe\u00f1a R, Madoz-G\u00farpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F<\/strong>, Rovira A, Albanell J. Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clin Cancer Res. 2021 Sep 15;27(18):5096-5108. doi: 10.1158\/1078-0432.CCR-20-2915. Epub 2021 Aug 12. PMID: 34385295.<\/li>\n\n\n\n
  6. Scientific Article 2020.<\/strong> Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hude\u010dek J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F<\/strong>, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020 May 12;6:16. doi: 10.1038\/s41523-020-0154-2. PMID: 32411818; PMCID: PMC7217824.<\/li>\n\n\n\n
  7. Scientific Article 2020.<\/strong> Zazo S, Gonz\u00e1lez-Alonso P, Mart\u00edn-Aparicio E, Chamizo C, Luque M, Sanz-\u00c1lvarez M, M\u00ednguez P, G\u00f3mez-L\u00f3pez G, Crist\u00f3bal I, Caram\u00e9s C, Garc\u00eda-Foncillas J, Eroles P, Lluch A, Arp\u00ed O, Rovira A, Albanell J, Madoz-G\u00farpide J, Rojo F<\/strong>. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer. Mol Cancer Ther. 2020 Aug;19(8):1696-1707. doi: 10.1158\/1535-7163.MCT-19-1172. Epub 2020 May 13. PMID: 32404410.<\/li>\n\n\n\n
  8. Scientific Article 2020.<\/strong> Gonz\u00e1lez-Alonso P, Zazo S, Mart\u00edn-Aparicio E, Luque M, Chamizo C, Sanz-\u00c1lvarez M, Minguez P, G\u00f3mez-L\u00f3pez G, Crist\u00f3bal I, Caram\u00e9s C, Garc\u00eda-Foncillas J, Eroles P, Lluch A, Arp\u00ed O, Rovira A, Albanell J, Piersma SR, Jimenez CR, Madoz-G\u00farpide J, Rojo F<\/strong>. The Hippo Pathway Transducers YAP1\/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer. Cancers (Basel). 2020 Apr 29;12(5):1108. doi: 10.3390\/cancers12051108. PMID: 32365528; PMCID: PMC7281325.<\/li>\n\n\n\n
  9. Scientific Article 2020.<\/strong> Fern\u00e1ndez-Nogueira P, Mancino M, Fuster G, L\u00f3pez-Plana A, Jauregui P, Almendro V, Enreig E, Men\u00e9ndez S, Rojo F,<\/strong> Noguera-Castells A, Bill A, Gaither LA, Serrano L, Recalde-Percaz L, Moragas N, Alonso R, Ametller E, Rovira A, Lluch A, Albanell J, Gascon P, Bragado P. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation. Clin Cancer Res. 2020 Mar 15;26(6):1432-1448. doi: 10.1158\/1078-0432.CCR-19-0353. Epub 2019 Nov 7. PMID: 31699826.<\/li>\n\n\n\n
  10. Scientific Article 2018.<\/strong> Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F<\/strong>, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estap\u00e9 A, Fern\u00e1ndez E, M\u00fcllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Mu\u00f1oz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+<\/sup>\u00a0breast cancer. Nat Cell Biol. 2018 Feb;20(2):211-221. doi: 10.1038\/s41556-017-0021-z. Epub 2018 Jan 22. Erratum in: Nat Cell Biol. 2018 Apr 19;: PMID: 29358704.<\/li>\n\n\n\n
  11. Scientific Article 2018.<\/strong> Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O’Toole S, Watkins DN, Cox TR, Samuel MS, Mart\u00edn M, Swarbrick A. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038\/s41467-018-05220-6. PMID: 30042390; PMCID: PMC6057940.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    During these years the AP group has established collaborations with different national and international groups, in the field of coordinated projects and projects of excellence of the ISCIII, European projects, of the Community of Madrid, etc. Within the IIS-FJD, we … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":324,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-337","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.precicolon.es\/index.php?rest_route=\/wp\/v2\/pages\/337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.precicolon.es\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.precicolon.es\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.precicolon.es\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.precicolon.es\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=337"}],"version-history":[{"count":7,"href":"https:\/\/www.precicolon.es\/index.php?rest_route=\/wp\/v2\/pages\/337\/revisions"}],"predecessor-version":[{"id":708,"href":"https:\/\/www.precicolon.es\/index.php?rest_route=\/wp\/v2\/pages\/337\/revisions\/708"}],"up":[{"embeddable":true,"href":"https:\/\/www.precicolon.es\/index.php?rest_route=\/wp\/v2\/pages\/324"}],"wp:attachment":[{"href":"https:\/\/www.precicolon.es\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}